Here’s a paradox: A new drug for Alzheimer’s disease, aducanumab, gets approved by the Food and Drug Administration through an accelerated process without sufficient data, although there was limited evidence that it works, leading three advisory board members to resign in protest. Meanwhile, mRNA coronavirus vaccines are not yet fully licensed despite massive evidence of their benefits.
Read the full article in The New York Times.
